AACHEN, Germany & SHANGHAI--(BUSINESS WIRE)--#ecls--MicroPort Scientific Corporation (hereinafter referred to as �MicroPort��) announced on October 4^th, 2021, through its critical care subsidiary, MicroPort Surgical B.V. (�MicroPort� Surgery�), has acquired 100% of the equity held by existing shareholders of Hemovent GmbH (hereinafter referred to as �Hemovent�) for a total cash consideration of up to �123 million. Upon completion of the acquisition, Hemovent will become a wholly owned subsidiary of MicroPort�.

Hemovent, established in 2013 in Aachen, Germany, is a medical device company specializing in the development of ground-breaking Extracorporeal Life Support (ECLS) systems. Hemovent�s flagship product, the MOBYBOX� system, is the first fully integrated ECLS system to manage both perfusion and gas exchange in a single device, and has set a new standard for ECMO devices in terms of mobility and ease of use.

MicroPort� has established its foothold in the critical care sector with its subsidiary MicroPort� Surgery, which is committed to providing patients with comprehensive medical solutions for cardiac surgery, emergency and critical care. The Hemovent acquisition will further MicroPort��s strategy in emergency and critical care, through the combination of Cardiopulmonary Bypass (CPB) with the R&D, manufacturing and commercialization of ECMO products.

Mr. Zhiguang Cheng, Senior Vice President of MicroPort� Surgery, said, �Relying on years of expertise accumulated in cardiac systemic circulation, MicroPort� Surgery has been actively expanding its product portfolio into the intensive care field. The light, portable and easy to operate features of MOBYBOX� enable us to expand the application of this innovative ECMO technology to better meet the medical needs in the post-pandemic era. After the completion of the acquisition, MicroPort� Surgery will pursue device internationalization through a US FDA filing and the clinical registration of MOBYBOX� in China.�

Mr. Christof Lenz, CEO of Hemovent, added, �We are extremely happy with our new partner MicroPort� who can leverage Hemovent�s team efforts with its profound resources, industry expertise and global reach in order to raise our unique technology to the next level. We are looking forward to a significant scale up of business activities in our current Aachen facility, as well as growing our international operations and distribution chains. We trust in our MOBYBOX� system to be an eventual game changer for the application of ECLS, as it offers unrivalled mobility and ease of use in this area of critical care.�

To date Hemovent has been backed by a consortium of institutional investors led by MIG Capital.

William Blair acted as exclusive financial advisor, and LUTZ | ABEL acted as exclusive legal advisor to Hemovent�s shareholders. TRENZ Attorneys acted as exclusive legal advisor to Hemovent. Freshfields Bruckhaus Deringer acted as exclusive legal advisor to Microport�.

The transaction has received all the necessary and customary regulatory approvals. Completion of the transaction is expected in Q4/2021.

CAUTION: The Hemovent MOBYBOX System is not approved for distribution or sale outside of the EU.

Contacts

Christof Lenz, Hemovent GmbH, +49-241-990-133-0, [email protected]